Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia

被引:28
作者
Takamatsu, Koutaro [1 ]
Nakane, Shunya [1 ,2 ]
Suzuki, Shigeaki [3 ]
Kosaka, Takayuki [1 ]
Fukushima, Satoshi [4 ]
Kimura, Toshihiro [4 ]
Miyashita, Azusa [4 ]
Mukaino, Akihiro [1 ]
Yamakawa, Shiori [1 ]
Watanabe, Keisuke [1 ]
Jinnin, Masatoshi [4 ]
Komohara, Yoshihiro [5 ]
Ihn, Hironobu [4 ]
Ando, Yukio [1 ]
机构
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Fac Life Sci, Kumamoto, Japan
[2] Kumamoto Univ Hosp, Dept Mol Neurol & Therapeut, Kumamoto, Japan
[3] Keio Univ, Dept Neurol, Sch Med, Tokyo, Japan
[4] Kumamoto Univ, Grad Sch Med Sci, Dept Dermatol & Plast Surg, Fac Life Sci, Kumamoto, Japan
[5] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Fac Life Sci, Kumamoto, Japan
基金
日本学术振兴会;
关键词
DILATED CARDIOMYOPATHY; UNTREATED MELANOMA; NIVOLUMAB; IPILIMUMAB; THERAPY; AUTOANTIBODIES; PATIENT; SUSCEPTIBILITY; ASSOCIATION; CTLA4;
D O I
10.1002/acn3.654
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Immune checkpoint inhibitors sometimes cause neuromuscular adverse events. Although a few cases of myasthenia gravis with hyperCKemia triggered by immune checkpoint inhibitors have been described, conclusive evidence remains limited. We conducted a systematic review of published cases of myasthenia gravis with hyperCKemia related to immune checkpoint inhibitors. Moreover, we tested anti-striational antibodies in the case of myasthenia gravis with myositis after nivolumab administration. We located 17 published case reports. Anti-striational antibodies were tested in six cases and five cases were positive. Our systematic analyses revealed poor prognosis in myasthenia gravis combined hyperCKemia with immune checkpoint inhibitors.
引用
收藏
页码:1421 / 1427
页数:7
相关论文
共 42 条
[1]   A CASE OF NEW-ONSET ANTI-BODYPOSITIVE MYASTHENIA GRAVIS IN A PATIENT TREATED WITH PEMBROLIZUMAB FOR MELANOMA [J].
Alnahhas, Iyad ;
Wong, Jason .
MUSCLE & NERVE, 2017, 55 (06) :E25-+
[2]   Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody [J].
Bilen, Mehmet Asim ;
Subudhi, Sumit K. ;
Gao, Jianjun ;
Tannir, Nizar M. ;
Tu, Shi-Ming ;
Sharma, Padmanee .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
[3]  
Bot Ilja, 2013, Pract Neurol, V13, P278, DOI 10.1136/practneurol-2012-000447
[4]   Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder [J].
Chang, Elaine ;
Sabichi, Anita L. ;
Sada, Yvonne H. .
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (03) :114-116
[5]   Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer A case report and literature review [J].
Chen, Jia-Hung ;
Lee, Kang-Yun ;
Hu, Chaur-Jong ;
Chung, Chen-Chih .
MEDICINE, 2017, 96 (50)
[6]   Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma Case report [J].
Chen, Yu-Hsiu ;
Liu, Feng-Cheng ;
Hsu, Chang-Hung ;
Chian, Chih-Feng .
MEDICINE, 2017, 96 (27)
[7]   Refractory myasthenia gravis exacerbation triggered By pembrolizumab [J].
Earl, Damien E. ;
Loochtan, Aaron I. ;
Bedlack, Richard S. .
MUSCLE & NERVE, 2018, 57 (04) :E120-E121
[8]   CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis [J].
Gerdes, Lisa Ann ;
Held, Kathrin ;
Beltran, Eduardo ;
Berking, Carola ;
Prinz, Joerg C. ;
Junker, Andreas ;
Tietze, Julia K. ;
Ertl-Wagner, Birgit ;
Straube, Andreas ;
Kuempfel, Tania ;
Dornmair, Klaus ;
Hohlfeld, Reinhard .
ANNALS OF NEUROLOGY, 2016, 80 (02) :294-300
[9]   Myasthenia triggered by immune checkpoint inhibitors: New case and literature review [J].
Gonzalez, Natalia L. ;
Puwanant, Araya ;
Lu, Angela ;
Marks, Stanley M. ;
Zivkovic, Sasa A. .
NEUROMUSCULAR DISORDERS, 2017, 27 (03) :266-268
[10]   Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Myasthenia Gravis [J].
Higuchi, Osamu ;
Hamuro, Johko ;
Motomura, Masakatsu ;
Yamanashi, Yuji .
ANNALS OF NEUROLOGY, 2011, 69 (02) :418-422